Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The ...
A brief course of morphine provided some relief for patients with cough related to idiopathic pulmonary fibrosis (IPF) in a small, phase II double-blind crossover trial. Two weeks of low-dose ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Between baseline and day 21, there was a –67% change in ...
In cystic fibrosis, ETI significantly reduced daily cough frequency and increased physical activity levels in patients aged 12 and older.
In a recent study published in The Lancet Respiratory Medicine, a team of researchers compared the efficacy of the controlled release of low-dose morphine as an antitussive treatment against that of a ...
Cough imposed a substantial symptom burden in patients with hypersensitivity pneumonitis (HP). Corticosteroid therapy over 3 months was tied to reduced patient-reported cough severity and improved ...
The panel voted 12 to 1 that the evidence does not demonstrate a clinically meaningful benefit. The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee has voted against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results